logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Oncolytics Biotech Inc.

ONC.TO

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizerā€¦ read more

Healthcare

Biotechnology

23 years

CAD

Exclusive to Premium users

Price

per share adjusted in CAD

$1.42

Price

-4.70%

-$0.07

$1.49

Previous Close

$1.47

Open

Premium

52w Discount
Market Cap

$137.175m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$31.503m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.39

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$6.494m

$19.702m

Assets

$13.208m

Liabilities

$1m

Debt
Debt to Assets

5.1%

-

Debt to EBITDA
Free Cash Flow

-$19.221m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in CAD.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.